LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

Home・Aandelen Lijst・Corcept Therapeutics Inc

Corcept Therapeutics Inc

Gesloten

SectorGezondheidszorg

84.78 1.09

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

82.6

Max

85.67

Belangrijke statistieken
By Trading Economics
Inkomsten	-16M 19M
Verkoop	13M 208M
K/W Sectorgemiddelde	91.701 80.03
Winstmarge	9.323
Werknemers	500
EBITDA	-11M 16M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+61.74% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	591M 8.4B
Vorige openingsprijs	83.69
Vorige sluitingsprijs	84.78

Nieuwssentiment

By Acuity

93%

356 / 374 Rangschikking in Healthcare

Corcept Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 dec 2025, 20:41 UTC

Winsten

Belangrijke Marktbewegers

America's Car-Mart Rises on Better-Than-Expected 2Q Revenue, $300 Million Term Loan

4 dec 2025, 18:14 UTC

Acquisities, Fusies, Overnames

Big Yellow Says It Will Terminate Takeover Talks With Blackstone

4 dec 2025, 17:43 UTC

Belangrijke Marktbewegers

Acquisities, Fusies, Overnames

Brera Holdings Signs Non-Binding Term Sheet to Acquire RockawayX

4 dec 2025, 17:01 UTC

Winsten

TD Bank Pushes Up Dividend After Underlying Earnings, Revenue Beat Expectations -- Update

4 dec 2025, 23:45 UTC

Marktinformatie

Nikkei May Decline Amid Caution Over U.S. Labor Market, Japan Earnings -- Market Talk

4 dec 2025, 23:45 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

4 dec 2025, 21:54 UTC

Marktinformatie

Global Equities Roundup: Market Talk

4 dec 2025, 21:54 UTC

Marktinformatie

Warehouse's Strategy to Lift Margins Easier Said Then Done -- Market Talk

4 dec 2025, 21:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

4 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

4 dec 2025, 21:48 UTC

Marktinformatie

Scales Hits Mark With Earnings Guidance -- Market Talk

4 dec 2025, 21:37 UTC

Winsten

Aerospace Start-Up Beta Posts Its First Earnings Report. The Stock Rises. -- Barrons.com

4 dec 2025, 21:36 UTC

Winsten

These Stocks Moved the Most Today: Meta Platforms, Salesforce, Snowflake, UiPath, Micron, Dollar General, Kroger, and More -- Barrons.com

4 dec 2025, 20:15 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

4 dec 2025, 20:15 UTC

Marktinformatie

Think Tank Calls For Bank of Canada Rate Hold Next Week -- Market Talk

4 dec 2025, 20:04 UTC

Marktinformatie

Natural Gas Futures Extend Gains as U.S. Grows Cold -- Market Talk

4 dec 2025, 19:54 UTC

Marktinformatie

Oil Futures Bolstered by Lasting Ukraine War, U.S. Macro Outlook -- Market Talk

4 dec 2025, 19:44 UTC

Acquisities, Fusies, Overnames

EQB CEO: PC Financial Deal Adds Scale to Compete With Larger Canadian Banks

4 dec 2025, 19:44 UTC

Acquisities, Fusies, Overnames

EQB CEO: PC Financial Tie-Up Brings Scale to Reach More Customers

4 dec 2025, 19:44 UTC

Acquisities, Fusies, Overnames

Equitable Bank Deal for PC Financial Adds Heft to Compete With Canada's Big Banks -- Interview

4 dec 2025, 19:33 UTC

Marktinformatie

Gold Inches Higher as Traders Continue to Mull ADP Jobs Report -- Market Talk

4 dec 2025, 19:01 UTC

Acquisities, Fusies, Overnames

Paramount Raises Concerns About Netflix's Bid for Warner Bros. Discovery -- WSJ

4 dec 2025, 19:01 UTC

Acquisities, Fusies, Overnames

Paramount Wrote to Warner Bros. Discovery Again Wednesday -- WSJ

4 dec 2025, 19:01 UTC

Acquisities, Fusies, Overnames

Paramount Wrote Netflix Deal With Warner Bros. Would Likely 'Never Close,' Monday Letter Says -- WSJ

4 dec 2025, 19:01 UTC

Acquisities, Fusies, Overnames

Another Round of Bids for Warner Bros. Discovery Due Thursday, Sources Say -- WSJ

4 dec 2025, 18:58 UTC

Marktinformatie

U.S.-Venezuela Military Tension Expected to Lift Oil Prices -- Market Talk

4 dec 2025, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

4 dec 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

4 dec 2025, 16:41 UTC

Marktinformatie

Gold Rises as Traders Await U.S. Inflation Data -- Market Talk

4 dec 2025, 16:33 UTC

Marktinformatie

Winsten

Salesforce Customers Are Gaining Confidence in Agentforce -- Market Talk

Peer Vergelijking

Prijswijziging

Corcept Therapeutics Inc Prognose

Koersdoel

By TipRanks

61.74% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 135.33 USD 61.74%

Hoogste 145 USD

Laagste 121 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corcept Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Corcept Therapeutics Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

356 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.